KNIGHT CAPITOL CONSULTANTS for REGENXBIO
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Potential changes in the corporate tax rate or other provisions of interest to business (Build Back Better Act, H.R. 5376 or any successor legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin Hatch; Health Policy Director, Senator Orrin Hatch. |
Health Issues HCR
Potential legislation implementing value based purchasing for pharmaceuticals (no specific bill); Possible provisions related to Drug Pricing Legislation that affect biological products' development and marketing, including deliberations associated with the Build Back Better Act (H.R. 5376) and the Infrastructure, Investment and Jobs Act (PL 117-58). Possible authority for a new ARPA-H.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch |
Medicare/Medicaid MMM
Inclusion of provisions affecting the reimbursement of gene therapies that may be contained in any drug pricing legislation or budget legislation (H.R. 3 or its successor; the Build Back Better Act (HR 5376)/or any successor reconciliation bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Pharmacy PHA
Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.